InflaRx to present phase 3 vilobelimab data at dermatology meeting

March 18, 2026 7:30 AM

InflaRx N.V. (NASDAQ: IFRX) announced that phase 3 study results for vilobelimab in pyoderma gangrenosum will be presented during a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found